Cancer nanomedicine: From drug delivery to imaging

Science Translational Medicine

Volumn 5, Issue 216, 2013, Pages

  Chow, Edward Kai Hua ^a,b   Ho, Dean ^c,d,e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UCLA SCHOOL OF DENTISTRY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON NANOMATERIAL; DOXORUBICIN; GOLD NANOPARTICLE; NANOMATERIAL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE SILENCING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; LIVER CANCER; MAGNETOTHERAPY; MATERIAL STATE; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SURFACE PROPERTY;

EID: 84892650579     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005872     Document Type: Review

References (112)

1. M. E. Fox, F. C. Szoka, J. M. Fréchet, Soluble polymer carriers for the treatment of cancer: The importance of molecular architecture. Acc. Chem. Res. 42, 1141-1151 (2009).
2. C. Schwarz, W. Mehnert, J. S. Lucks, R. H. Müller, Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J. Control. Release 30, 83-96 (1994).
3. S. K. Sahoo, V. Labhasetwar, Nanotech approaches to drug delivery and imaging. Drug Discov. Today 8, 1112-1120 (2003).
4. V. P. Torchilin, Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73, 137-172 (2001).
5. B. M. Discher, Y. Y. Won, D. S. Ege, J. C. Lee, F. S. Bates, D. E. Discher, D. A. Hammer, Polymersomes: Tough vesicles made from diblock copolymers. Science 284, 1143-1146 (1999).
6. A. K. Patri, I. J. Majoros, J. R. Baker Jr., Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 6, 466-471 (2002).
7. R. Langer, N. A. Peppas, Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 49, 2990-3006 (2003).
8. R. K. O'Reilly, C. J. Hawker, K. L. Wooley, Cross-linked block copolymer micelles: Functional nanostructures of great potential and versatility. Chem. Soc. Rev. 35, 1068-1083 (2006).
9. C. J. Hawker, K. L. Wooley, The convergence of synthetic organic and polymer chemistries. Science 309, 1200-1205 (2005).
10. L. M. Ensign, B. C. Tang, Y. Y. Wang, T. A. Tse, T. Hoen, R. Cone, J. Hanes, Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 4, 138ra79 (2012).
11. E. A. Nance, G. F. Woodworth, K. A. Sailor, T. Y. Shih, Q. Xu, G. Swaminathan, D. Xiang, C. Eberhart, J. Hanes, A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl. Med. 4, 149ra119 (2012).
12. N. A. Peppas, J. Z. Hilt, A. Khademhosseini, R. Langer, Hydrogels in biology and medicine: From molecular principles to bionanotechnology. Adv. Mater. 18, 1345-1360 (2006).
13. O. C. Farokhzad, S. Jon, A. Khademhosseini, T. N. Tran, D. A. Lavan, R. Langer, Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res. 64, 7668-7672 (2004).
14. A. Khademhosseini, R. Langer, Nanobiotechnology - Drug delivery and tissue engineering. Chem. Eng. Prog. 102, 38-42 (2006).
15. D. S. Katti, K. W. Robinson, F. K. Ko, C. T. Laurencin, Bioresorbable nanofiber-based systems for wound healing and drug delivery: Optimization of fabrication parameters. J. Biomed. Mater. Res. B Appl. Biomater. 70, 286-296 (2004).
16. J. D. Hartgerink, E. Beniash, S. I. Stupp, Peptide-amphiphile nanofibers: A versatile scaffold for the preparation of self-assembling materials. Proc. Natl. Acad. Sci. U.S.A. 99, 5133-5138 (2002).
17. X. Q. Zhang, X. Xu, R. Lam, D. Giljohann, D. Ho, C. A. Mirkin, Strategy for increasing drug solubility and efficacy through covalent attachment to polyvalent DNA-nanoparticle conjugates. ACS Nano 5, 6962-6970 (2011).
18. I. H. El-Sayed, X. Huang, M. A. El-Sayed, Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 239, 129-135 (2006).
19. 2-oligonucleotide nanocomposites. Nat. Mater. 2, 343-346 (2003).
20. J. S. Kim, E. Kuk, K. N. Yu, J. H. Kim, S. J. Park, H. J. Lee, S. H. Kim, Y. K. Park, Y. H. Park, C. Y. Hwang, Y. K. Kim, Y. S. Lee, D. H. Jeong, M. H. Cho, Antimicrobial effects of silver nanoparticles. Nanomedicine 3, 95-101 (2007).
21. K. Ajima, T. Murakami, Y. Mizoguchi, K. Tsuchida, T. Ichihashi, S. Iijima, M. Yudasaka, Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano 2, 2057-2064 (2008).
22. K. Ajima, M. Yudasaka, T. Murakami, A. Maigné, K. Shiba, S. Iijima, Carbon nanohorns as anticancer drug carriers. Mol. Pharm. 2, 475-480 (2005).
23. A. Bianco, K. Kostarelos, M. Prato, Applications of carbon nanotubes in drug delivery. Curr. Opin. Chem. Biol. 9, 674-679 (2005).
24. Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, H. Dai, Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68, 6652-6660 (2008).
25. Z. Liu, S. M. Tabakman, Z. Chen, H. Dai, Preparation of carbon nanotube bioconjugates for biomedical applications. Nat. Protoc. 4, 1372-1382 (2009).
26. E. K. Chow, X. Q. Zhang, M. Chen, R. Lam, E. Robinson, H. Huang, D. Schaffer, E. Osawa, A. Goga, D. Ho, Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci. Transl. Med. 3, 73ra21 (2011).
27. H. Huang, E. Pierstorff, E. Osawa, D. Ho, Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett. 7, 3305-3314 (2007).
28. H. Huang, E. Pierstorff, E. Osawa, D. Ho, Protein-mediated assembly of nanodiamond hydrogels into a biocompatible and biofunctional multilayer nanofilm. ACS Nano 2, 203-212 (2008).
29. V. N. Mochalin, O. Shenderova, D. Ho, Y. Gogotsi, The properties and applications of nanodiamonds. Nat. Nanotechnol. 7, 11-23 (2011).
30. K. K. Liu, W. W. Zheng, C. C. Wang, Y. C. Chiu, C. L. Cheng, Y. S. Lo, C. Chen, J. I. Chao, Covalent linkage of nanodiamond-paclitaxel for drug delivery and cancer therapy. Nanotechnology 21, 315106 (2010).
31. M. Liong, J. Lu, M. Kovochich, T. Xia, S. G. Ruehm, A. E. Nel, F. Tamanoi, J. I. Zink, Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2, 889-896 (2008).
32. H. Meng, W. X. Mai, H. Zhang, M. Xue, T. Xia, S. Lin, X. Wang, Y. Zhao, Z. Ji, J. I. Zink, A. E. Nel, Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7, 994-1005 (2013).
33. H. Meng, M. Xue, T. Xia, Z. Ji, D. Y. Tarn, J. I. Zink, A. E. Nel, Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5, 4131-4144 (2011).
34. J. Kim, J. E. Lee, J. Lee, J. H. Yu, B. C. Kim, K. An, Y. Hwang, C. H. Shin, J. G. Park, J. Kim, T. Hyeon, Magnetic fluorescent delivery vehicle using uniform mesoporous silica spheres embedded with monodisperse magnetic and semiconductor nanocrystals. J. Am. Chem. Soc. 128, 688-689 (2006).
35. E. S. Day, L. Zhang, P. A. Thompson, J. A. Zawaski, C. C. Kaffes, M. W. Gaber, S. M. Blaney, J. L. West, Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine 7, 1133-1148 (2012).
36. L. M. Manus, D. J. Mastarone, E. A. Waters, X. Q. Zhang, E. A. Schultz-Sikma, K. W. Macrenaris, D. Ho, T. J. Meade, Gd(III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett. 10, 484-489 (2010).
37. G. von Maltzahn, J. H. Park, K. Y. Lin, N. Singh, C. Schwöppe, R. Mesters, W. E. Berdel, E. Ruoslahti, M. J. Sailor, S. N. Bhatia, Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater. 10, 545-552 (2011).
38. Z. J. Deng, S. W. Morton, E. Ben-Akiva, E. C. Dreaden, K. E. Shopsowitz, P. T. Hammond, Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 7, 9571-9584 (2013).
39. World Health Organization, GLOBOCAN 2008 cancer fact sheet; http://globocan.iarc.fr/.
40. American Cancer Society, Cancer facts and figures 2013; http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf.
41. R. K. Jain, Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-93 (1987).
42. U. Prabhakar, H. Maeda, R. K. Jain, E. M. Sevick-Muraca, W. Zamboni, O. C. Farokhzad, S. T. Barry, A. Gabizon, P. Grodzinski, D. C. Blakey, Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412 -2417 (2013).
43. J. Senior, J. C. Crawley, G. Gregoriadis, Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim. Biophys. Acta 839, 1-8 (1985).
44. M. C. Woodle, K. K. Matthay, M. S. Newman, J. E. Hidayat, L. R. Collins, C. Redemann, F. J. Martin, D. Papahadjopoulos, Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim. Biophys. Acta 1105, 193-200 (1992).
45. L. Moore, E. K. Chow, E. Osawa, J. M. Bishop, D. Ho, Diamond-lipid hybrids enhance chemotherapeutic tolerance and mediate tumor regression. Adv. Mater. 25, 3532-3541 (2013).
46. A. M. Gobin, M. H. Lee, N. J. Halas, W. D. James, R. A. Drezek, J. L. West, Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett. 7, 1929-1934 (2007).
47. N. J. Robert, C. L. Vogel, I. C. Henderson, J. A. Sparano, M. R. Moore, P. Silverman, B. A. Overmoyer, C. L. Shapiro, J. W. Park, G. T. Colbern, E. P. Winer, A. A. Gabizon, The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol. 31, 106-146 (2004).
48. J. W. Valle, A. Armstrong, C. Newman, V. Alakhov, G. Pietrzynski, J. Brewer, S. Campbell, P. Corrie, E. K. Rowinsky, M. Ranson, A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 29, 1029-1037 (2011).
49. S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, M. Ranson, Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90, 2085-2091 (2004).
50. A. L. van de Ven, P. Kim, O. Haley, J. R. Fakhoury, G. Adriani, J. Schmulen, P. Moloney, F. Hussain, M. Ferrari, X. Liu, S. H. Yun, P. Decuzzi, Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control. Release 158, 148-155 (2012).
51. Y. Ren, H. W. Cheung, G. von Maltzhan, A. Agrawal, G. S. Cowley, B. A. Weir, J. S. Boehm, P. Tamayo, A. M. Karst, J. F. Liu, M. S. Hirsch, J. P. Mesirov, R. Drapkin, D. E. Root, J. Lo, V. Fogal, E. Ruoslahti, W. C. Hahn, S. N. Bhatia, Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl. Med. 4, 147ra112 (2012).
52. P. L. Rodriguez, T. Harada, D. A. Christian, D. A. Pantano, R. K. Tsai, D. E. Discher, Minimal "self " peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975 (2013).
53. J. Hrkach, D. Von Hoff, M. Mukkaram Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J. J. Song, Y. H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P. W. Kantoff, N. H. Bander, C. Sweeney, O. C. Farokhzad, R. Langer, S. Zale, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39 (2012).
54. E. Ryschich, G. Huszty, H. P. Knaebel, M. Hartel, M. W. Büchler, J. Schmidt, Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur. J. Cancer. 40, 1418-1422 (2004).
55. E. R. Camp, C. Wang, E. C. Little, P. M. Watson, K. F. Pirollo, A. Rait, D. J. Cole, E. H. Chang, D. K. Watson, Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 20, 222-228 (2013).
56. N. Senzer, J. Nemunaitis, D. Nemunaitis, C. Bedell, G. Edelman, M. Barve, R. Nunan, K. F. Pirollo, A. Rait, E. H. Chang, Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 21, 1096-1103 (2013).
57. E. Ruoslahti, Specialization of tumour vasculature. Nat. Rev. Cancer 2, 83-90 (2002).
58. K. N. Sugahara, T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, D. R. Greenwald, E. Ruoslahti, Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035 (2010).
59. K. N. Sugahara, T. Teesalu, P. P. Karmali, V. R. Kotamraju, L. Agemy, O. M. Girard, D. Hanahan, R. F. Mattrey, E. Ruoslahti, Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16, 510-520 (2009).
60. P. Chaudhuri, A. Paraskar, S. Soni, R. A. Mashelkar, S. Sengupta, Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 3, 2505-2514 (2009).
61. A. S. Paraskar, S. Soni, K. T. Chin, P. Chaudhuri, K. W. Muto, J. Berkowitz, M. W. Handlogten, N. J. Alves, B. Bilgicer, D. M. Dinulescu, R. A. Mashelkar, S. Sengupta, Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc. Natl. Acad. Sci. U.S.A. 107, 12435-12440 (2010).
62. J. E. Podesta, K. T. Al-Jamal, M. A. Herrero, B. Tian, H. Ali-Boucetta, V. Hegde, A. Bianco, M. Prato, K. Kostarelos, Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 5, 1176-1185 (2009).
63. N. R. Soman, S. L. Baldwin, G. Hu, J. N. Marsh, G. M. Lanza, J. E. Heuser, J. M. Arbeit, S. A. Wickline, P. H. Schlesinger, Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J. Clin. Invest. 119, 2830-2842 (2009).
64. D. B. Longley, P. G. Johnston, Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292 (2005).
65. L. N. Abdullah, E. K. Chow, Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2, 3 (2013).
66. W. S. Dalton, J. J. Crowley, S. S. Salmon, T. M. Grogan, L. R. Laufman, G. R. Weiss, J. D. Bonnet, A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75, 815-820 (1995).
67. C. Lhommé, F. Joly, J. L. Walker, A. A. Lissoni, M. O. Nicoletto, G. M. Manikhas, M. M. Baekelandt, A. N. Gordon, P. M. Fracasso, W. L. Mietlowski, G. J. Jones, M. H. Dugan, Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol. 26, 2674-2682 (2008).
68. H. B. Man, H. Kim, H. J. Kim, E. Robinson, W. K. Liu, E. K. Chow, D. Ho, Synthesis of nanodiamond-daunorubicin conjugates to overcome multidrug chemoresistance in leukemia. Nanomedicine 10.1016/j.nano.2013.07.014 (2013).
69. M. E. Davis, J. E. Zuckerman, C. H. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
70. M. E. Davis, The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharm. 6, 659-668 (2009).
71. J. D. Heidel, J. Y. Liu, Y. Yen, B. Zhou, B. S. Heale, J. J. Rossi, D. W. Bartlett, M. E. Davis, Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res. 13, 2207-2215 (2007).
72. M. Koldehoff, N. K. Steckel, D. W. Beelen, A. H. Elmaagacli, Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin. Exp. Med. 7, 47-55 (2007).
73. S. A. Jensen, E. S. Day, C. H. Ko, L. A. Hurley, J. P. Luciano, F. M. Kouri, T. J. Merkel, A. J. Luthi, P. C. Patel, J. I. Cutler, W. L. Daniel, A. W. Scott, M. W. Rotz, T. J. Meade, D. A. Giljohann, C. A. Mirkin, A. H. Stegh, Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med. 5, 209ra152 (2013).
74. C. Loo, A. Lowery, N. Halas, J. West, R. Drezek, Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5, 709 -711 (2005).
75. L. B. Carpin, L. R. Bickford, G. Agollah, T. K. Yu, R. Schiff, Y. Li, R. A. Drezek, Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res. Treat. 125, 27-34 (2011).
76. X. Hu, X. Gao, Multilayer coating of gold nanorods for combined stability and biocompatibility. Phys. Chem. Chem. Phys. 13, 10028-10035 (2011).
77. R. K. Kannadorai, Q. Liu, Optimization in interstitial plasmonic photothermal therapy for treatment planning. Med. Phys. 40, 103301 (2013).
78. C. L. Chen, L. R. Kuo, S. Y. Lee, Y. K. Hwu, S. W. Chou, C. C. Chen, F. H. Chang, K. H. Lin, D. H. Tsai, Y. Y. Chen, Photothermal cancer therapy via femtosecond-laser-excited FePt nanoparticles. Biomaterials 34, 1128-1134 (2013).
79. P. Pouponneau, J. C. Leroux, G. Soulez, L. Gaboury, S. Martel, Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation. Biomaterials 32, 3481-3486 (2011).
80. L. Maggiorella, G. Barouch, C. Devaux, A. Pottier, E. Deutsch, J. Bourhis, E. Borghi, L. Levy, Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 8, 1167-1181 (2012).
81. P. R. Dal Monte, F. C. Szoka Jr., Antigen presentation by B cells and macrophages of cytochrome c and its antigenic fragment when conjugated to the surface of liposomes. Vaccine 7, 401-408 (1989).
82. M. Garinot, V. Fiévez, V. Pourcelle, F. Stoffelbach, A. des Rieux, L. Plapied, I. Theate, H. Freichels, C. Jérôme, J. Marchand-Brynaert, Y. J. Schneider, V. Préat, PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 120, 195-204 (2007).
83. D. N. Nguyen, K. P. Mahon, G. Chikh, P. Kim, H. Chung, A. P. Vicari, K. T. Love, M. Goldberg, S. Chen, A. M. Krieg, J. Chen, R. Langer, D. G. Anderson, Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl. Acad. Sci. U.S.A. 109, E797-E803 (2012).
84. S. Kageyama, S. Kitano, M. Hirayama, Y. Nagata, H. Imai, T. Shiraishi, K. Akiyoshi, A. M. Scott, R. Murphy, E. W. Hoffman, L. J. Old, N. Katayama, H. Shiku, Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci. 99, 601-607 (2008).
85. + T-cell responses in melanoma patients. Eur. J. Immunol. 42, 3049-3061 (2012).
86. X. G. Gu, M. Schmitt, A. Hiasa, Y. Nagata, H. Ikeda, Y. Sasaki, K. Akiyoshi, J. Sunamoto, H. Nakamura, K. Kuribayashi, H. Shiku, A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res. 58, 3385-3390 (1998).
87. S. Kitano, S. Kageyama, Y. Nagata, Y. Miyahara, A. Hiasa, H. Naota, S. Okumura, H. Imai, T. Shiraishi, M. Masuya, M. Nishikawa, J. Sunamoto, K. Akiyoshi, T. Kanematsu, A. M. Scott, R. Murphy, E. W. Hoffman, L. J. Old, H. Shiku, HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin. Cancer Res. 12, 7397-7405 (2006).
88. G. E. Peoples, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, A. Amin, S. Khoo, Z. A. Dehqanzada, J. M. Gurney, M. M. Woll, G. B. Ryan, C. E. Storrer, D. Craig, C. G. Ioannides, S. Ponniah, Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14, 797-803 (2008).
89. E. A. Scott, A. Stano, M. Gillard, A. C. Maio-Liu, M. A. Swartz, J. A. Hubbell, Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 33, 6211-6219 (2012).
90. O. A. Ali, D. Emerich, G. Dranoff, D. J. Mooney, In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, 8ra19 (2009).
91. R. W. Ross, A. L. Zietman, W. Xie, J. J. Coen, D. M. Dahl, W. U. Shipley, D. S. Kaufman, T. Islam, A. R. Guimaraes, R. Weissleder, M. Harisinghani, Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imaging 33, 301-305 (2009).
92. S. Jiang, A. A. Eltoukhy, K. T. Love, R. Langer, D. G. Anderson, Lipidoid-coated iron oxide nanoparticles for efficient DNA and siRNA delivery. Nano Lett. 13, 1059-1064 (2013).
93. M. Levy, N. Luciani, D. Alloyeau, D. Elgrabli, V. Deveaux, C. Pechoux, S. Chat, G. Wang, N. Vats, F. Gendron, C. Factor, S. Lotersztajn, A. Luciani, C. Wilhelm, F. Gazeau, Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials 32, 3988-3999 (2011).
94. C. Wong, T. Stylianopoulos, J. Cui, J. Martin, V. P. Chauhan, W. Jiang, Z. Popovic, R. K. Jain, M. G. Bawendi, D. Fukumura, Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. U.S.A. 108, 2426-2431 (2011).
95. J. Liu, S. K. Lau, V. A. Varma, R. A. Moffitt, M. Caldwell, T. Liu, A. N. Young, J. A. Petros, A. O. Osunkoya, T. Krogstad, B. Leyland-Jones, M. D. Wang, S. Nie, Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano 4, 2755- 2765 (2010).
96. S. D. Perrault, W. C. Chan, In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc. Natl. Acad. Sci. U.S.A. 107, 11194-11199 (2010).
97. B. Sana, E. Johnson, K. Sheah, C. L. Poh, S. Lim, Iron-based ferritin nanocore as a contrast agent. Biointerphases 5, FA48-FA52 (2010).
98. E. Tóth, R. D. Bolskar, A. Borel, G. González, L. Helm, A. E. Merbach, B. Sitharaman, L. J. Wilson, Water-soluble gadofullerenes: Toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc. 127, 799-805 (2004).
99. J. S. Ananta, B. Godin, R. Sethi, L. Moriggi, X. Liu, R. E. Serda, R. Krishnamurthy, R. Muthupillai, R. D. Bolskar, L. Helm, M. Ferrari, L. J. Wilson, P. Decuzzi, Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat. Nanotechnol. 5, 815-821 (2010).
100. M. F. Kircher, A. de la Zerda, J. V. Jokerst, C. L. Zavaleta, P. J. Kempen, E. Mittra, K. Pitter, R. Huang, C. Campos, F. Habte, R. Sinclair, C. W. Brennan, I. K. Mellinghoff, E. C. Holland, S. S. Gambhir, A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat. Med. 18, 829-834 (2012).
101. P. C. M. van Zijl, N. N. Yadav, Chemical exchange saturation transfer (CEST): What is in a name and what isn't? Magn. Reson. Med. 65, 927-948 (2011).
102. G. Liu, M. Moake, Y. E. Har-el, C. M. Long, K. W. Chan, A. Cardona, M. Jamil, P. Walczak, A. A. Gilad, G. Sgouros, P. C. van Zijl, J. W. Bulte, M. T. McMahon, In vivo multicolor molecular MR imaging using diamagnetic chemical exchange saturation transfer liposomes. Magn. Reson. Med. 67, 1106-1113 (2012).
103. K. W. Chan, G. Liu, X. Song, H. Kim, T. Yu, D. R. Arifin, A. A. Gilad, J. Hanes, P. Walczak, P. C. van Zijl, J. W. Bulte, M. T. McMahon, MRI-detectable pH nanosensors incorporated into hydrogels for in vivo sensing of transplanted-cell viability. Nat. Mater. 12, 268-275 (2013).
104. B. S. Ferguson, D. A. Hoggarth, D. Maliniak, K. Ploense, R. J. White, N. Woodward, K. Hsieh, A. J. Bonham, M. Eisenstein, T. E. Kippin, K. W. Plaxco, H. T. Soh, Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. Sci. Transl. Med. 5, 213ra165 (2013).
105. J. Reed, J. Chun, T. A. Zangle, S. Kalim, J. S. Hong, S. E. Pefley, X. Zheng, J. K. Gimzewski, M. A. Teitell, Rapid, massively parallel single-cell drug response measurements via live cell interferometry. Biophys. J. 101, 1025-1031 (2011).
106. C. P. Sun, T. Usui, F. Yu, I. Al-Shyoukh, J. Shamma, R. Sun, C. M. Ho, Integrative systems control approach for reactivating Kaposi 's sarcoma-associated herpesvirus (KSHV) with combinatory drugs. Integr. Biol. 1, 123-130 (2009).
107. P. K. Wong, F. Yu, A. Shahangian, G. Cheng, R. Sun, C. M. Ho, Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc. Natl. Acad. Sci. U.S.A. 105, 5105-5110 (2008).
108. X. Sun, S. Vilar, N. P. Tatonetti, High-throughput methods for combinatorial drug discovery. Sci. Transl. Med. 5, 205rv1 (2013).
109. H. Meng, Y. Zhao, J. Dong, M. Xue, Y. S. Lin, Z. Ji, W. X. Mai, H. Zhang, C. H. Chang, C. J. Brinker, J. I. Zink, A. E. Nel, Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 7, 10048-10065 (2013).
110. Food and Drug Administration Draft Guidance, Considering whether an FDA-regulated product involves the application of nanotechnology; www.fda.gov/regulatoryinformation/guidances/ucm257698.htm.
111. Food and Drug Administration Consumer Update, FDA continues dialogue on 'nano' regulation; www.fda.gov/forconsumers/consumerupdates/ucm258462.htm.
112. European Medicines Agency Reflection Paper, Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products; www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/02/ WC500138390.pdf.